1
|
Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, Heikura T, Turpeinen S, Laidinen S, Takalo T, Ylä-Herttuala S. 15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A– and Placental Growth Factor–Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression. Circ Res 2008; 102:177-84. [DOI: 10.1161/circresaha.107.155556] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Human 15-lipoxygenase-1 (15-LO-1) is an oxidizing enzyme capable of producing reactive lipid hydroperoxides. 15-LO-1 and its products have been suggested to be involved in many pathological conditions, such as inflammation, atherogenesis, and carcinogenesis. We used adenovirus-mediated gene transfers to study the effects of 15-LO-1 on vascular endothelial growth factor (VEGF)-A
165
– and placental growth factor (PlGF)-induced angiogenesis in rabbit skeletal muscles. 15-LO-1 significantly decreased all angiogenic effects induced by these growth factors, including capillary perfusion, vascular permeability, vasodilatation, and an increase in capillary number. The effects are attributable to the reduction in the amount of VEGF-A
165
and PlGF transcripts by 15-LO-1, resulting in reduced protein expression. The most likely mediator of the VEGF family–induced capillary vasodilatation is nitric oxide (NO), which is produced by NO synthases. Endothelial NO synthase protein expression and NO synthase activity were significantly induced by VEGF-A
165
, and these inductions were reduced by 15-LO-1. VEGF-A
165
induces its angiogenic effects primarily via vascular endothelial growth factor receptor (VEGFR)2, and also PlGF mediates angiogenic signaling via VEGFR2, even though it binds to VEGFR1. VEGFR2 expression is induced by peroxisome proliferator-activating receptor γ. We showed by quantitative RT-PCR and immunohistochemistry that expression of endogenous rabbit peroxisome proliferator-activating receptor γ and VEGFR2 were significantly increased in the growth factor–transduced muscles, but these inductions were efficiently prevented by 15-LO-1. In conclusion, the results suggest that expression of 15-LO-1 has an efficient antiangiogenic effect in vivo via reduction in growth factor mRNA levels, NO bioactivity, and VEGFR2 expression.
Collapse
Affiliation(s)
- Helena Viita
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Johanna Markkanen
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Emmi Eriksson
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Markku Nurminen
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Kati Kinnunen
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Mohan Babu
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Tommi Heikura
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Sanna Turpeinen
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Svetlana Laidinen
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Teemu Takalo
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| | - Seppo Ylä-Herttuala
- From the Department of Biotechnology and Molecular Medicine (H.V., J.M., E.E., M.N., K.K., M.B., T.H., S.T., S.L., T.T., S.Y.-H.), A. I. Virtanen Institute for Molecular Sciences, and Department of Medicine (S.Y.-H.), University of Kuopio; and Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Finland
| |
Collapse
|